<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03774875</url>
  </required_header>
  <id_info>
    <org_study_id>CC-10004-PSOR-020</org_study_id>
    <secondary_id>U1111-1224-8381</secondary_id>
    <secondary_id>2018-002850-58</secondary_id>
    <nct_id>NCT03774875</nct_id>
  </id_info>
  <brief_title>A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life</brief_title>
  <acronym>EMBRACE</acronym>
  <official_title>A Phase 4, Multi-center, Randomized, Double-blind, Placebo-controlled Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 4, multi-center, randomized, placebo-controlled, double-blind study of the&#xD;
      impact of apremilast on quality of life, efficacy, and safety in subjects with manifestations&#xD;
      of plaque psoriasis and impaired quality of life.&#xD;
&#xD;
      Approximately 255 subjects will be randomized 2 (apremilast):1 (placebo) in approximately 6&#xD;
      to 10 countries in Western Europe. Subjects will be block-randomized equally to each of the&#xD;
      manifestations of psoriasis (scalp psoriasis, nail psoriasis, palmoplantar psoriasis, genital&#xD;
      psoriasis, and psoriasis in visible locations). If subjects present with multiple&#xD;
      manifestations, they will be allocated to the manifestation which is most severe, as&#xD;
      determined by the subject.&#xD;
&#xD;
      However, all manifestations will be assessed for efficacy at each study visit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 28, 2019</start_date>
  <completion_date type="Actual">November 4, 2021</completion_date>
  <primary_completion_date type="Actual">February 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who achieve a ≥ 4-point reduction in DLQI from baseline</measure>
    <time_frame>Week16</time_frame>
    <description>Dermatology Life Quality Index (DLQI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve a ≥ 4-point reduction in DLQI from baseline</measure>
    <time_frame>Week 32 and 52</time_frame>
    <description>Dermatology Life Quality Index (DLQI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in DLQI</measure>
    <time_frame>Week 16, 32 and 52</time_frame>
    <description>Dermatology Life Quality Index (DLQI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in Itch NRS score</measure>
    <time_frame>Week 16, 32 and 52</time_frame>
    <description>Itch Numeric Rating Scale (NRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in skin discomfort/pain VAS</measure>
    <time_frame>Week 16, 32 and 52</time_frame>
    <description>Skin Discomfort/Pain Visual Analog Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change in BSA affected by psoriasis</measure>
    <time_frame>Week 16, 32 and 52</time_frame>
    <description>Body Surface Area (BSA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve PBI score of ≥ 1</measure>
    <time_frame>Week 16, 32 and 52</time_frame>
    <description>Patient Benefit Index (PBI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve PASI &lt; 3</measure>
    <time_frame>Week 16, 32 and 52</time_frame>
    <description>Psoriasis Area Severity Index (PASI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in EQ-5D score</measure>
    <time_frame>Week 16 and 52</time_frame>
    <description>European Quality of Life 5- Dimension (EQ-5D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in WPAI domain scores</measure>
    <time_frame>Week 16 and 52</time_frame>
    <description>Work Productivity and Activity Impairment Questionnaire (WPAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent Adverse events</measure>
    <time_frame>From enrollment until at least 28 days after completion of study treatment, an average of 1 year.</time_frame>
    <description>Frequency and incidence rate of any TEAE by SOC, PT, severity, and relationship of adverse events (AEs) to investigational product (IP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in body weight</measure>
    <time_frame>Throughout the duration of the apremilast treatment, an average of 1 year.</time_frame>
    <description>Frequency of clinically significant changes in body weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in waist circumference</measure>
    <time_frame>Throughout the duration of the apremilast treatment, an average of 1 year.</time_frame>
    <description>Frequency of clinically significant changes in waist circumference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in vital signs</measure>
    <time_frame>Throughout the duration of the apremilast treatment, an average of 1 year.</time_frame>
    <description>Frequency of clinically significant changes in vital signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in laboratory findings</measure>
    <time_frame>Throughout the duration of the apremilast treatment, an average of 1 year.</time_frame>
    <description>Frequency of clinically significant changes in laboratory findings.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">277</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Apremilast 30 mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take oral tablets of apremilast for up to 52 weeks (30 mg twice daily).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by Apremilast 30mg twice daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will take placebo for 16 weeks. After Week 16, subjects will be switched to receive apremilast (30 mg twice daily) until Week 52.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast (CC-10004)</intervention_name>
    <description>This study will randomize subjects to either apremilast 30 mg BID or placebo comparator in a 2:1 ratio, respectively. Subjects randomized to apremilast will receive dose-titration for the initial 5 days. Apremilast subjects will receive &quot;dummy&quot; titration at wk 16 to maintain the blinding of the original treatment assignments. Investigational product (IP) will be dispensed in blinded dose cards until Week 20. Thereafter, IP will be dispensed in open-label bottles.</description>
    <arm_group_label>Apremilast 30 mg twice daily</arm_group_label>
    <other_name>Otezla</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects randomized to the placebo treatment group will receive placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally twice daily for 16 weeks.</description>
    <arm_group_label>Placebo followed by Apremilast 30mg twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast (CC-10004)</intervention_name>
    <description>Beginning at Week 16 and after a 5-day titration with apremilast, subjects initially randomized to placebo will be switched to receive apremilast 30 mg BID for 36 weeks (52 weeks total). Investigational product (IP) will be dispensed in blinded dose cards until Week 20. Thereafter, IP will be dispensed in open-label bottles</description>
    <arm_group_label>Placebo followed by Apremilast 30mg twice daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must satisfy the following criteria to be enrolled in the study:&#xD;
&#xD;
          1. Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF).&#xD;
&#xD;
          2. Subject must understand and voluntarily sign an ICF prior to any study-related&#xD;
             assessments/procedures being conducted.&#xD;
&#xD;
          3. Subject is willing and able to adhere to the study visit schedule and other protocol&#xD;
             requirements.&#xD;
&#xD;
          4. Subject has diagnosis of chronic plaque psoriasis for at least 6 months prior to&#xD;
             baseline, that cannot be controlled by topical therapy.&#xD;
&#xD;
          5. Subject has a PASI score ranging from ≥3 to ≤ 10 at baseline.&#xD;
&#xD;
          6. Subject has a DLQI score &gt; 10 at baseline.&#xD;
&#xD;
          7. Subject has presence of ≥ 1 clinical manifestations of plaque psoriasis, defined as at&#xD;
             least one of the following:&#xD;
&#xD;
               1. Moderate to severe scalp psoriasis, defined as Scalp Physician Global Assessment&#xD;
                  (ScPGA) ≥ 3&#xD;
&#xD;
               2. Nail psoriasis, defined as onycholysis and onychodystrophy in at least 2&#xD;
                  fingernails&#xD;
&#xD;
               3. Moderate to severe genital plaque psoriasis, defined as modified static&#xD;
                  Physicians Global Assessment of Genitalia (sPGA-G) ≥ 3&#xD;
&#xD;
               4. Moderate to severe palmoplantar psoriasis, defined as Palmoplantar Psoriasis&#xD;
                  Physicians Global Assessment (PPPGA) ≥ 3&#xD;
&#xD;
               5. Moderate to severe plaque psoriasis in visible locations (dorsal hand, face,&#xD;
                  neck, and hairline) with static Physicians Global Assessment (sPGA) ≥ 3&#xD;
&#xD;
          8. Subject must be in general good health (except for psoriasis) as judged by the&#xD;
             Investigator, based on medical history, physical examination, and clinical&#xD;
             laboratories.&#xD;
&#xD;
             (NOTE: The definition of good health means a subject does not have uncontrolled&#xD;
             significant co-morbid conditions.)&#xD;
&#xD;
          9. Subject must have failed to respond to, or be contraindicated to, or intolerant to&#xD;
             other systemic therapy,including, but not limited to, cyclosporine, methotrexate,&#xD;
             acitretin, psoralen and ultraviolet-A-light (PUVA) fumaric acid esters or biologic&#xD;
             therapies.&#xD;
&#xD;
         10. Subjects (in Italy only) must be non-responder to, contraindicated to, or intolerant&#xD;
             to other systemic therapy (including cyclosporine, methotrexate, or PUVA) AND also be&#xD;
             contraindicated to, or intolerant to biologics.&#xD;
&#xD;
         11. Females of childbearing potential (FCBP)† must have a negative pregnancy test at&#xD;
             Screening and Baseline. While on investigational product and for at least 28 days&#xD;
             after taking the last dose of investigational product, FCBP who engage in activity in&#xD;
             which conception is possible must use one of the approved contraceptive options&#xD;
             described below:&#xD;
&#xD;
        Option 1: Any one of the following highly effective methods: hormonal contraception (oral,&#xD;
        injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal&#xD;
        ligation; or partner's vasectomy; OR Option 2: Male or female condom (latex condom or&#xD;
        nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]) PLUS&#xD;
        one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with&#xD;
        spermicide; or (c) contraceptive sponge with spermicide.&#xD;
&#xD;
        NOTE: Option 2 may not be acceptable as a highly effective contraception option in all&#xD;
        countries per local guidelines/regulations.&#xD;
&#xD;
        Exclusion Criteria: DO NOT USE ACROYNMS&#xD;
&#xD;
        The presence of any of the following will exclude a subject from enrollment:&#xD;
&#xD;
          1. Subject has any condition, including other inflammatory diseases or dermatologic&#xD;
             conditions, which confounds the ability to interpret data from the study, including&#xD;
             other types of psoriasis (ie, erythrodermic, or guttate), other than plaque psoriasis&#xD;
             or inverse psoriasis.&#xD;
&#xD;
          2. Subject has history of drug-induced psoriasis.&#xD;
&#xD;
          3. Subject has arthritis that requires systemic treatment.&#xD;
&#xD;
          4. Subject unable to avoid use of tanning booths for at least 4 weeks prior to baseline&#xD;
             and during study.&#xD;
&#xD;
          5. Subject is currently enrolled in any other clinical trial involving an investigational&#xD;
             product.&#xD;
&#xD;
          6. Other than psoriasis, subject has history of clinically significant or uncontrolled&#xD;
             disease (as determined by the Investigator), including the presence of laboratory&#xD;
             abnormalities, cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic,&#xD;
             renal, hematologic, immunologic disease, or other major disease, which places the&#xD;
             subject at unacceptable risk if he/she were to participate in the study&#xD;
&#xD;
          7. Prior history of suicide attempt at any time in the subject's lifetime prior to&#xD;
             signing the informed consent, or major psychiatric illness requiring hospitalization&#xD;
             within the last 3 years prior to signing the informed consent.&#xD;
&#xD;
          8. Subjects with severe renal impairment, defined by eGFR (estimated glomerular&#xD;
             filtration rate) or CLcr (creatinine clearance) less than 30 mL/min, are also&#xD;
             categorized as having Stage 4 Chronic Kidney Disease (CKD), and are excluded from the&#xD;
             study.&#xD;
&#xD;
          9. Malignancy or history of malignancy or myeloproliferative or lymphoproliferative&#xD;
             disease within the past 3 years, except for treated (ie, cured) basal cell or squamous&#xD;
             cell in situ skin carcinomas.&#xD;
&#xD;
         10. Bacterial infections requiring treatment with oral or injectable antibiotics, or&#xD;
             significant viral or fungal infections, within 4 weeks of Screening. Any treatment for&#xD;
             such infections must have been completed and the infection cured, at least 4 weeks&#xD;
             prior to Screening and no new or recurrent infections prior to the Baseline Visit..&#xD;
&#xD;
         11. Subject has received a live vaccine within 3 months of baseline or plans to do so&#xD;
             during study.&#xD;
&#xD;
         12. Subject is a pregnant or breastfeeding (lactating) woman.&#xD;
&#xD;
         13. Subject has used topical therapy within 2 weeks of randomization (including, but not&#xD;
             limited to, topical corticosteroids, retinoids or vitamin D analog preparations,&#xD;
             tacrolimus, pimecrolimus, anthralin/dithranol, or moisturizers which contain urea or&#xD;
             salicylic acid). Use of phototherapy within 4 weeks prior to randomization. Use of&#xD;
             conventional systemic therapy or systemic corticosteroids within 4 weeks prior to&#xD;
             randomization, except for conditions other than psoriasis or psoriatic arthritis. Use&#xD;
             of biologic therapy within 5 pharmacokinetic half-lives.&#xD;
&#xD;
         14. Prior treatment with apremilast, or participation in a clinical study, involving&#xD;
             apremilast.&#xD;
&#xD;
         15. Subject has any condition that confounds the ability to interpret data from the study.&#xD;
&#xD;
         16. Subject has history of allergy or hypersensitivity to any components of the IP&#xD;
             (including placebo).&#xD;
&#xD;
         17. Subject has rare hereditary problem of galactose intolerance, lapp lactase deficiency&#xD;
             or glucose-galactose malabsorption.&#xD;
&#xD;
         18. Subject's most severe manifestation corresponds to a manifestation whose randomization&#xD;
             block has already been fully enrolled. (NOTE: This will allow to block-randomize&#xD;
             equally to each of the manifestations of plaque psoriasis specified in Inclusion&#xD;
             Criteria #7. An alert from IRT (interactive response technology) system will notify&#xD;
             Investigators of the recruitment status of each of the manifestation randomization&#xD;
             blocks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grenoble Cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon Cedex 03</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rouen Cedex</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valence</city>
        <zip>26953</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valenciennes</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Augsburg</city>
        <zip>86179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10247</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>13086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>13507</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bochum</city>
        <zip>44803</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Langenau</city>
        <zip>89129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>München</city>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli, Campania</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perugia</city>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Badalona</city>
        <state>Cataluña</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manises</city>
        <state>Comunidad Valenciana</state>
        <zip>46940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Castellon de la Plana</city>
        <zip>12004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barnet</city>
        <zip>EN5 3DJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2WB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 3EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bury Saint Edmunds</city>
        <zip>IP33 2QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dumfries</city>
        <zip>DG1 4AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gloucester</city>
        <zip>GL1 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Isleworth</city>
        <zip>TW7 6AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS7 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newport</city>
        <zip>NP18 3XQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Redhill</city>
        <zip>RH1 5RH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stourbridge</city>
        <zip>DY8 4JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 11, 2018</study_first_submitted>
  <study_first_submitted_qc>December 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2018</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Apremilast</keyword>
  <keyword>CC-10004</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Psoriasis manifestations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>http://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

